Eight children with severe autoimmune diseases who did not respond to conventional therapies were able to completely stop ...

Daiichi Sankyo begins patient dosing in phase 1/2 trial of DS3790 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: Tokyo Friday, February 6, 2026, 10:00 Hrs [I ...

Nonresponse to bridging therapy and high lymphocyte count were predictive of parkinsonism and nonrelapse mortality (NRM) after treatment with ciltacabtagene autoleucel (cilta-cel; Carvykti) in ...

Daniel Kirby, Chief Commercial Officer of Iovance, stated, “The real world Amtagvi data with impressive response rates, ...

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal ...

A team of researchers at VCU Massey Comprehensive Cancer Center discovered an innovative way to use a drug already approved ...

Combination antiretroviral therapy (ART) has transformed HIV-1 infection into a chronic condition with near-normal life expectancy. For more than two decades, the standard regimen has been a ...

The data showed that a subset of killer T cells that also interact with EBV are more prevalent in people with the chronic autoimmune disease.

A woman in her 60s with a history of atrial fibrillation, hypertension and dyslipidaemia was admitted to the Intensive Care ...